Department of Chemistry, Yonsei University, Seoul 03722, Republic of Korea.
Department of Psychiatry, SMG-SNU Boramae Medical Center, Seoul 07061, Republic of Korea.
J Chromatogr A. 2018 Sep 21;1568:91-100. doi: 10.1016/j.chroma.2018.07.018. Epub 2018 Jul 5.
Alzheimer's disease (AD) is an irreversible neurodegenerative disorder with the clinical symptom of the progressive loss of cognitive function and mild cognitive impairment (MCI) is a translational state between cognitive changes of normal aging and AD. Lipid metabolism and pathogenesis of Alzheimer's disease (AD) are closely linked. Despite obviously discrete lipidome constitutions across lipoproteins, lipidomic approaches of AD has been mostly conducted without considering lipoprotein-dependent alterations. This study introduces a combination of asymmetrical flow field-flow fractionation (AF4) and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry (nUHPLC-ESI-MS/MS) for a comprehensive lipid profiling in different lipoprotein level of patients plasma with AD and amnestic MCI in comparison to age-matched healthy controls. Lipoproteins in plasma samples were size-sorted by a semi-preparative scale AF4, followed by non-targeted lipid identification and high speed targeted quantitation with nUHPLC-ESI-MS/MS. It shows 14 significantly altered high abundance lipids in AD, exhibiting >2-fold increases (p < 0.01) in LDL/VLDL including triacylglycerol, ceramide, phosphatidylethanolamine, and diacylglycerol. Three lipid species (triacylglycerol 50:1, diacylglycerol 18:1_18:1, and phosphatidylethanolamine 36:2) showing a strong correlation with the degree of brain atrophy were found as candidate species which can be utilized to differentiate the early stage of MCI when simple Mini-Mental State Examination results were statistically incorporated. The present study elucidated lipoprotein-dependent alterations of lipids in progression of MCI and further to AD which can be utilized for the future development of lipid biomarkers to enhance the predictability of disease progress.
阿尔茨海默病(AD)是一种不可逆转的神经退行性疾病,其临床症状为认知功能进行性丧失,轻度认知障碍(MCI)是认知正常老化与 AD 之间的转化状态。脂代谢与阿尔茨海默病(AD)的发病机制密切相关。尽管脂蛋白之间的脂质组组成明显不同,但 AD 的脂质组学方法大多没有考虑脂蛋白依赖性变化。本研究介绍了一种组合方法,即不对称流场流分离(AF4)和纳流超高效液相色谱-串联质谱(nUHPLC-ESI-MS/MS),用于对 AD 患者和遗忘型轻度认知障碍(MCI)患者血浆中不同脂蛋白水平的全面脂质谱进行分析,并与年龄匹配的健康对照组进行比较。通过半制备规模的 AF4 对血浆样品中的脂蛋白进行大小排序,然后用 nUHPLC-ESI-MS/MS 进行非靶向脂质鉴定和高速靶向定量。结果显示,AD 患者的 14 种高丰度脂质显著改变,其中 LDL/VLDL 中的甘油三酯、神经酰胺、磷脂酰乙醇胺和二酰基甘油等增加了 2 倍以上(p < 0.01)。发现三种脂质物种(甘油三酯 50:1、二酰基甘油 18:1_18:1 和磷脂酰乙醇胺 36:2)与脑萎缩程度有很强的相关性,可作为候选物种,当将简单的迷你精神状态检查结果统计纳入时,可用于区分 MCI 的早期阶段。本研究阐明了 MCI 向 AD 进展过程中脂蛋白依赖性脂质变化,可用于未来开发脂质生物标志物,提高疾病进展的可预测性。